5-hydroxy-8-(1,1-dimethylallyl)psoralen, 8-isoamylenoxypsoralen, imperatorin
| Name | Pentosalen | ||
| PubChem CID | 10212 | ||
| Molecular Weight | 270.28g/mol | ||
| Synonyms |
5-hydroxy-8-(1,1-dimethylallyl)psoralen, 8-isoamylenoxypsoralen, imperatorin |
||
| Formula | C₁₆H₁₄O₄ | ||
| SMILES | CC(=CCOC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2)C | ||
| InChI | 1S/C16H14O4/c1-10(2)5-7-19-16-14-12(6-8-18-14)9-11-3-4-13(17)20-15(11)16/h3-6,8-9H,7H2,1-2H3 | ||
| InChIKey | OLOOJGVNMBJLLR-UHFFFAOYSA-N | ||
| CAS Number | 482-44-0 | ||
| ChEMBL ID | CHEMBL453805 | ||
| ChEBI ID | CHEBI:5885 | ||
| KEGG ID | C09269 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | BaiZhi | ||
| Use Part | Root | ||
| Habitat | HeBei, HeNan, ShanXi, NeiMengGu, Shaanxi | ||
| Flavor | Pungent | ||
| Meridian Tropism | Stomach; Large Intestine; Lung | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Apiales
-->Family: Apiaceae
-->Genus: Angelica
-->Species: Angelica dahurica
|
||
| Pair Name | Pentosalen, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | MCL1 | hsa4170 |
| In Vitro Model | HepG3 | Hepatoblastoma | Homo sapiens (Human) | CVCL_Y479 |
| Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 | |
| PLC/PRF/5 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0485 | |
| Huh-7 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0336 | |
| Result | We found that the addition of imperatorin significantly reversed the resistance to cisplatin in cisplatin-resistant HCC cells, which was Mcl-1 dependent. In summary, our study revealed that combination with imperatorin could enhance the antitumor activity of cisplatin via targeting Mcl-1 and reverse the resistance to cisplatin in HCC. | |||
